熱點掃描 | 醫藥股反彈，藥明巨諾漲超6%
uSMART盈立智投7月7日消息，港股三大指數延續低迷態勢，恆指跌0.96%，報27802.98點，成交額602.30億，國企指數跌1.42%，恆生科技指數跌0.98%，港股通淨流入9.49億。
生物醫藥板塊反彈，截止10：46，藥明巨諾漲超6%，BCMA靶向CAR-T療法臨牀試驗申請獲受理；藥明生物、藥明康德漲超4%，開拓藥業、石藥集團均漲超3%，康龍化成、泰格醫藥漲超2%。機構稱，醫藥龍頭公司將受惠於CED新規，馬太效應更加凸顯。
家電股表現亮眼，截止10：46，海爾智家漲超4%，VESYNC漲超3%，海信家電漲近3%，創科實業漲近1%，
體育用品板塊盤初翻紅後繼續拉昇，截止10：46，特步漲超5%，股價再創歷史新高李寧漲超4%，361度、中國動向漲超3%，安踏漲超1%。
大型科技股保持頹勢，截止10：46，嗶哩嗶哩大跌超5%，汽車之家跌超4%，百度、快手跌超3%，京東、騰訊均跌超2%，美團、網易、中芯國際跌超1%；小米股價幾乎持平，新東方在線、金山軟件漲超1%。市場繼續擔憂監管對科技股的影響，隔夜美股中概股大跌。
石油股走弱，截止10：46，中國石油股份跌超2%，中國海洋石油、中國石油化工股份跌超1%。週二，WTI原油期貨失守73美元/桶，日內跌幅一度超過4%。布倫特原油期貨失守75美元關口。OPEC+談判破裂，消息最初推動油價上漲，但隨後油價回落，交易員關注這場衝突將導致一些國有油企增加供應並開始增加原油出口的可能性。
有色金屬板塊下挫，截止10：46，中國鋁業、中國宏橋、江銅、中國有色礦業跌超2%，紫金礦業、招金礦業跌超1%。
個股方面，截止10：46，今日兩支新股表現各異，朝聚眼科大漲超27%，報13.50元，成交額13.35億，而另一支港股新貴小鵬汽車則跌近2%，報162元，成交額7.67億；港交所漲超4%，IPO結算週期縮短至T+2，最早明年四季度實施；中國恆大跌幅擴大至4%，報9.57港元，爲2017年5月以來最低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
